Recent U.S. Customs and Border Protection rulings from CROSS, searchable by HTS code, keyword, or ruling number.
In your letter dated May 28, 2026, you requested a tariff classification ruling. Tadalafil, imported in dosages of 2.5 mg, 5 mg, 10 mg and 20 mg tablets, is a phosphodiesterase 5 (PDE5) inhibitor. It is primarily indicated for the treatment of erectile dysfunction. It is also indicated for the treatment of benign prostatic hyperplasia, and pulmonary arterial hypertension.
In your letter dated April 2, 2026, you requested a tariff classification ruling. Sugammadex Injection, imported in 200 mg/2 mL (100 mg/mL), is a selective relaxant binding agent. It is indicated for the reversal of neuromuscular blockades induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.
In your letter dated March 4, 2026, you requested a tariff classification ruling. Tranexamic Acid, imported in 650 mg tablets, is a synthetic derivative of lysine used as an antifibrinolytic. It is used to reduce or prevent hemorrhagic episodes, especially in the context of hyperfibrinolytic disorders.
In your letter dated March 3, 2026, you requested a tariff classification ruling. Sodium Phenylbutyrate, imported in 500 mg tablets, is a nitrogen-binding agent or ammonia scavenger. It is used as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
Source: rulings.cbp.gov (CROSS). This index holds New York rulings from the recent period and the Headquarters rulings they cite. It is not the full CROSS database of 222,467 rulings, and it does not hold every Headquarters ruling. New rulings usually appear here within a few days of CBP publishing them; a ruling published long after its number was assigned can take several weeks. Revoked, modified and proposed marks come from the weekly Customs Bulletin, where CBP publishes most such actions under 19 U.S.C. 1625(c), read here from the Nov 2024 issues onward, and from the subjects of indexed Headquarters rulings. A revocation is marked from the date it takes effect. The absence of a mark is not confirmation that a ruling is still in effect. A ruling letter is binding on CBP only for the particular transaction or issue it describes (19 CFR 177.9). Confirm the text and status on CROSS before relying on a ruling. Not legal advice.